Skip to main content
IRD
NASDAQ Life Sciences

Director-Affiliated Fund Sells $7.4M in Opus Genetics Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.36
Mkt Cap
$361.396M
52W Low
$0.901
52W High
$5.81
52W Position info
384% above low
Off High info
25% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IRD has more than doubled off its 52-week low of $0.901.

Summary

A director-affiliated institutional fund sold $7.395 million worth of Opus Genetics common stock in an open market transaction, representing a significant reduction in its holdings.


Key Events · Ownership and Investor Activity · IRD

  • Significant Insider Sale

    Foundation Fighting Blindness Retinal Degeneration Fund, an entity with director representation, sold 1,700,000 shares of common stock for $7,395,000.

  • Large Stake Reduction

    This sale represents approximately 2.05% of the company's market capitalization and reduces the fund's direct holdings to 3,792,171 shares.

  • Follows Recent Financing & Losses

    The sale occurs after Opus Genetics reported a substantial Q1 2026 net loss and secured new financing packages, including a $35 million tranche in April.


Analysis · IRD · Life Sciences

Foundation Fighting Blindness Retinal Degeneration Fund, an institutional investor with director representation on the board, sold 1.7 million shares for $7.395 million. This significant sale, representing over 2% of the company's market capitalization, could be interpreted as a reduction in conviction by a major institutional holder. This follows a period of significant financing activities and a substantial Q1 net loss reported by Opus Genetics.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 35.8% of the 1706 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IRD was trading at $4.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $361.4M. The 52-week trading range was $0.90 to $5.81. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IRD - Latest Insights

IRD
Sep 09, 2026, 10:48 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $5.52
Real-time Price: $6.07 info
Change: +$0.5531 (+10%) info
Market Cap: $505.257M info
IRD
Sep 09, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.57
Real-time Price: $6.07 info
Change: +$1.50 (+33%) info
Market Cap: $505.257M info
IRD
Sep 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.64
Real-time Price: $6.07 info
Change: +$1.43 (+31%) info
Market Cap: $505.257M info
IRD
Aug 06, 2026, 8:24 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $3.91
Real-time Price: $6.07 info
Change: +$2.16 (+55%) info
Market Cap: $505.257M info
IRD
Aug 06, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.75
Real-time Price: $6.07 info
Change: +$2.32 (+62%) info
Market Cap: $505.257M info